Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › benralizumab

benralizumab

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of benralizumab

22 trials tracked of benralizumab: 17 in phase 3 or 4 and 11 with published results. The most-cited published study has 1035 citations.

22Trials tracked
17Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 1 Phase 3 16 Phase 2 4 Phase 1 1
  1. Phase 3 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy Completed · 1,035 cited
  2. Phase 3 A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA Completed · 309 cited
  3. Phase 3 Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Completed · 173 cited
  4. Phase 3 Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Completed · 139 cited
  5. Phase 3 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Completed · 139 cited
  6. Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma Completed · 122 cited
Show 16 more trials
  1. Phase 3 Benralizumab for Eosinophilic Gastritis (BEGS) Completed · 64 cited
  2. Phase 3 PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma Completed · 30 cited
  3. Phase 3 A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 27 cited
  4. Phase 4 FAsenra Safety Trial in India Completed
  5. Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Completed
  6. Phase 3 Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home Completed
  7. Phase 3 Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma Completed
  8. Phase 3 Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home Completed
  9. Phase 3 A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation Completed
  10. Phase 3 Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics Completed
  11. Phase 3 A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist Completed
  12. Phase 2 A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). Completed
  13. Phase 2 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Completed
  14. Phase 2 Effect of Benralizumab in Atopic Dermatitis Completed
  15. Phase 2 Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Completed
  16. Phase 1 Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks
Allergy & Immunology Cohort
Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks New Asthma Shot May Cut Severe Attacks to Zero
This prospective, single-arm, multicenter, phase IV study evaluated benralizumab in 138 benralizumab-naïve adults (18–75 years) with severe …
A new injection appears safe and effective at reducing severe asthma attacks in adults.
Frontiers Apr 21, 2026
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Frontiers Apr 16, 2026
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD
Oncology Sys. Review
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD A Tricky Immune Messenger Behind Severe Asthma
This systematic review evaluated IL-5-targeted therapies, multi-target combination therapies, bispecific antibodies, and small-molecule inhi…
A protein called IL-5 fuels severe asthma, but new drugs targeting multiple immune pathways at once may finally help patients who haven't re…
Frontiers Apr 14, 2026